SCHEMBL7343249

SCHEMBL7343249

COc1cc(NC(=O)c2ccc3cc(C=NN)ccc3c2)cc(OC)c1OC

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
STAT3 P40763 1/20 0.54
ATM Q13315 1/20 0.52
GAA P10253 1/20 0.51
MAPK1 P28482 1/20 0.51
PLAU P00749 5/20 0.50
P4HTM Q9NXG6 1/20 0.48
PLG P00747 1/20 0.48
PLAT P00750 1/20 0.47
PTPN11 Q06124 1/20 0.47
NAMPT P43490 1/20 0.47
SMN1; SMN2 Q16637 2/20 0.46
NPC1 O15118 2/20 0.46
CASP3 P42574 2/20 0.46
RAB9A P51151 2/20 0.46
SENP7 Q9BQF6 2/20 0.46
NQO2 P16083 1/20 0.46
TP53 P04637 1/20 0.46
MAPT P10636 1/20 0.46
ABCB1 P08183 1/20 0.45
MEN1 O00255 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7340942 0.87 PLAU (0.67) GAAPLAUPLGPLATPTPN11
SCHEMBL9709123 0.80 ATM (0.69) ATMGAAMAPK1PLAUP4HTM
SCHEMBL7336457 0.80 NPC1 (0.53) PLAUPLGPLATSMN1; SMN2NPC1
SCHEMBL7340171 0.80 RAB9A (0.44) PLAUPLGPLATPTPN11NPC1
SCHEMBL7343223 0.80 PLAU (0.74) STAT3ATMGAAMAPK1PLAU
SCHEMBL7341753 0.79 MEN1 (0.53) GAAPLAUPLGNAMPTSMN1; SMN2
SCHEMBL7340329 0.78 PLAU (0.63) PLAUPLGPLATSMN1; SMN2NPC1
SCHEMBL7337325 0.78 PLAU (0.58) PLAUPLGPLATSMN1; SMN2NPC1
SCHEMBL7337311 0.78 PLAU (0.58) PLAUPLGPLATSMN1; SMN2NPC1
SCHEMBL7335937 0.77 DEGS1 (0.57) NPC1CASP3RAB9ASENP7NQO2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20010049374-A1 Urokinase inhibitors STEELE ANDREW W (US) 2001-12-06 US disclosed
US-6284796-B1 NAPHTHAMIDINE COMPOUNDS ABBOTT LABORATORIES 2001-09-04 US disclosed
US-6258822-B1 ENZYME INHIBITORS OF NAPHTHALENE AMIDINE COMPOUNDS ABBOTT LABORATORIES 2001-07-10 US disclosed
EP-1000018-A2 UROKINASE INHIBITORS Abbott Laboratories (US) 2000-05-17 EP disclosed
WO-1999005096-A2 UROKINASE INHIBITORS ABBOTT LABORATORIES (US) 1999-02-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010049374-A1 Urokinase inhibitors SERPINE1, PLAU, SERPINB1 STAT3 3629/4885ATM 3337/4885GAA 193/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.